Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
RBC Capital analyst Gregory Renza reiterates Morphic Holding (NASDAQ:MORF) with a Sector Perform and maintains $57 price tar...
Stifel analyst Alex Thompson maintains Morphic Holding (NASDAQ:MORF) with a Hold and raises the price target from $30 to $57.
The Russell 2000 index of small caps recorded its best weekly performance since October 2023, surging over 6%, driven by lower-...
Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and ...
BMO Capital analyst Evan David Seigerman downgrades Morphic Holding (NASDAQ:MORF) from Outperform to Market Perform and rais...
TD Cowen analyst Ritu Baral downgrades Morphic Holding (NASDAQ:MORF) from Buy to Hold.
RBC Capital analyst Gregory Renza downgrades Morphic Holding (NASDAQ:MORF) from Outperform to Sector Perform and lowers the ...
The CNN Money Fear and Greed index slightly decreased, remaining in Neutral zone. US stocks mixed, with S&P 500 at record h...
